Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350
26 5월 2006 - 5:33AM
PR Newswire (US)
WESTMINSTER, Colo., May 25 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) is disclosing the following
information about a grant of restricted stock awarded to Paul L.
Berns as an inducement to his entering into employment with the
Company, in press release form, as required by NASD Marketplace
Rule 4350(i)(1)(A). As an inducement for Mr. Berns to join the
Company as its President and Chief Executive Officer, on the first
date of his employment with the Company, March 9, 2006, Mr. Berns
was granted 300,000 shares of restricted stock of the Company (the
"Restricted Stock"). The Restricted Stock vests over a four-year
period, with 25% of the Restricted Stock vesting on each of the
first four anniversaries of the date of grant, subject to Mr.
Berns' continued employment with the Company through such vesting
dates. All of the above information, as well as additional
information regarding Mr. Berns' employment agreement with the
Company, is contained in a Form 8-K that was filed with the
Securities and Exchange Commission on March 14, 2006. About Allos
Therapeutics, Inc. Allos Therapeutics, Inc. (NASDAQ:ALTH) is a
biopharmaceutical company focused on developing and commercializing
innovative small molecule therapeutics for the treatment of cancer.
The Company's lead product candidate, EFAPROXYN(TM) (efaproxiral),
is a synthetic small molecule designed to sensitize hypoxic, or
oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN
is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases
originating from breast cancer. The Company's other product
candidates are: PDX (pralatrexate), a small molecule
chemotherapeutic agent (DHFR inhibitor) currently under
investigation in patients with non-small cell lung cancer and
Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic
agent bioactivated by the enzyme DT-diaphorase currently under
evaluation in patients with advanced solid tumors. For more
information, please visit the Company's web site at:
http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc.
CONTACT: Jennifer Neiman, Manager, Corporate Communications of
Allos Therapeutics, +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles